Shares of Astellas Pharma Inc. (OTCMKTS:ALPMY – Get Free Report) gapped up prior to trading on Monday. The stock had previously closed at $16.51, but opened at $17.10. Astellas Pharma shares last traded at $16.96, with a volume of 51,594 shares traded.
Analysts Set New Price Targets
Separately, Zacks Research cut shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy”.
Get Our Latest Analysis on Astellas Pharma
Astellas Pharma Stock Up 1.5%
The company has a debt-to-equity ratio of 0.16, a current ratio of 1.20 and a quick ratio of 0.93. The firm has a 50-day moving average of $15.25 and a 200 day moving average of $14.82. The stock has a market capitalization of $30.93 billion, a price-to-earnings ratio of 12.53 and a beta of 0.05.
Astellas Pharma (OTCMKTS:ALPMY – Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The company reported $0.35 earnings per share for the quarter, missing the consensus estimate of $0.41 by ($0.06). The company had revenue of $3.98 billion for the quarter, compared to analyst estimates of $3.79 billion. Astellas Pharma had a return on equity of 26.13% and a net margin of 16.18%. As a group, sell-side analysts forecast that Astellas Pharma Inc. will post 1.40 earnings per share for the current fiscal year.
Astellas Pharma Company Profile
Astellas Pharma Inc. is a Japan-based pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company was formed in 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical, and is headquartered in Tokyo. Astellas develops treatments across areas including oncology, urology, immunology and women’s health. Its medicines include Xtandi (enzalutamide), used to treat certain forms of prostate cancer, and Prograf (tacrolimus), an immunosuppressant used in organ transplantation.
Featured Articles
- Five stocks we like better than Astellas Pharma
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
- Embraer’s Record Backlog Looks Promising, But Can It Keep Its Margins Climbing?
- Could Big Buybacks Be the Next Catalyst for These 3 AI Stocks?
- 3 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?
Receive News & Ratings for Astellas Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astellas Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
